Skip to main content
. 2019 Feb 9;3(2):e175. doi: 10.1097/HS9.0000000000000175

Table 2.

Preferred and Alternative First-Line Therapy of Symptomatic CLL According to Prognostic and Clinic Subgroups

graphic file with name hs9-3-e175-g004.jpg